Unknown

Dataset Information

0

Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment.

ABSTRACT: The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101 HCV-1-infected patients were compared to genotype findings determined by direct core sequencing. Eleven (11%) samples were misclassified. Given the influence of the HCV-1-subtype in the anti-HCV therapy response, an alternative classification method is warranted.

SUBMITTER: Guelfo JR 

PROVIDER: S-EPMC4313243 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment.

Guelfo Javier R JR   Macias Juan J   Neukam Karin K   Di Lello Federico A FA   Mira Jose A JA   Merchante Nicolas N   Mancebo María M   Nuñez-Torres Rocío R   Pineda Juan A JA   Real Luis M LM  

Journal of clinical microbiology 20140820 11

The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101 HCV-1-infected patients were compared to genotype findings determined by direct core sequencing. Eleven (11%) samples were misclassified. Given the influence of the HCV-1-subtype in the anti-HCV therapy response, an alternative classification method is warranted. ...[more]

Similar Datasets

Genomics No HCV-1 Subtype Misclassification by LiPA 2.0
| PRJEB21943 | ENA
Unknown Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.
| S-EPMC4135880 | biostudies-literature
Unknown Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.
| S-EPMC3754683 | biostudies-literature
Unknown Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis.
| S-EPMC6531202 | biostudies-literature
Unknown Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.
| S-EPMC8237141 | biostudies-literature
Unknown Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China.
| S-EPMC8552672 | biostudies-literature
Unknown Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6.
| S-EPMC4187793 | biostudies-literature
Unknown Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.
| S-EPMC6207923 | biostudies-literature
Unknown Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus.
| S-EPMC4736847 | biostudies-literature
Unknown Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
| S-EPMC5901397 | biostudies-literature